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Abstract 
Introduction 
Patients with nocturia have to face many hurdles before being diagnosed and treated properly. 
The aim of this paper is to: summarize the nocturia patient pathway, explore how nocturia is 
diagnosed and treated in the real world and use the Delphi method to develop a practical 
algorithm with a focus on what steps need to be taken before prescribing desmopressin. 
Methods 
Evidence comes from existing guidelines (Google, PubMed), International Consultation on 
Incontinence‐Research Society (ICI‐RS) 2017, prescribing information and a Delphi panel (3 
rounds). The International Continence Society initiated this study, the authors represent the 
ICI‐RS, European Association of Urology, and Society of Urodynamics, Female Pelvic 
Medicine and Urogenital Reconstruction (SUFU). 
Results 
Diagnostic packages: consensus on, history taking for all causalities, intake diary (fluid, food) 
and bladder diary, not for its duration. Pelvic (women) or rectal (men) examination, prostate‐
specific antigen, serum sodium check (SSC), renal function, endocrine screening: when 
judged necessary. Timing or empty stomach when SSC is not important. Therapeutic 
packages: the safe candidates for desmopressin can be phenotyped as no polydipsia, 
heart/kidney failure, severe leg edema or obstructive sleep apnea syndrome. Lifestyle 
interventions may be useful. Initiating desmopressin: risk management consensus on three 
clinical pictures. 
Follow‐up of desmopressin therapy: there was consensus on SSC day 3 to 7, and at 1 month. 
Stop therapy if SSC is <130 mmol/L regardless of symptoms. Stop if SSC is 130 to 
135 mmol/L with symptoms of hyponatremia. 
Conclusion 
A summary of the nocturia patient pathway across different medical specialists is useful in 
the visualization and phenotyping of patients for diagnosis and therapy. By summarizing 
basic knowledge of desmopressin, we aim to ease its initiation and shorten the patient journey 
for nocturia. 
1 INTRODUCTION 
Nocturia was defined in 2002 as a complaint that the individual has to wake at night one or 
more times to void.11 It affects a high proportion of adults.2 Nevertheless, for a long time, the 
symptom received very little specific research attention as it was considered just one of a 
number of lower urinary tract symptoms (LUTS) indicating overactive bladder (OAB) or 
benign prostatic obstruction (BPO). In recent years, however, there has been growing 
recognition that it is a specific symptom in its own right, with wide‐ranging pathophysiology 
(including blood pressure changes, cardiac dysfunction, fluid shift into the lower limbs, 
polyuria, sleep apnea, insomnia, pharmacotherapy, and polypharmacy). Furthermore, it is 
associated with significant negative outcomes in terms of patient health, sleep, and quality of 
life. Yet there is no consensus on how to identify and manage nocturia patients for the best 
possible outcomes. 
During the 2017 meeting of the International Consultation on Incontinence‐Research Society 
(ICI‐RS) in Bristol, a nocturia think‐tank discussed how to study the gaps in our knowledge 
to develop a practical patient‐oriented diagnostic and therapeutic algorithm for nocturia.3 It 
was obvious that the many and varied causes of the condition are underdiagnosed and that 
many clinicians of different disciplines see patients with nocturia without paying specific 
attention to diagnosing and treating their excessive nocturnal voiding. 
Nocturia guidelines are mainly hidden within broader LUTS guidelines because nocturia has 
historically been linked primarily to OAB and BPO, even though its main cause is nocturnal 
polyuria (NP).5 A one‐year delay between onset of LUTS symptoms and consultation of a 
medical professional has been reported.6 Patients with nocturia are treated by healthcare 
providers from numerous different disciplines because nocturia is prevalent in many other 
conditions, such as cardiovascular disease, diabetes, and OAB. However, the specific 
condition of nocturia is ignored by most specialities, and only rarely does it improve with 
treatment of other underlying conditions. Different medical disciplines diagnose and treat 
nocturia or its underlying diseases using their own guidelines and recommendations based on 
levels of evidence available from prior research and literature. Diagnostic and therapeutic 
“packages” from each discipline are helpful to visualize the approach to nocturia that is taken 
in clinical practice. 
No single treatment can effectively treat nocturia in all contexts. However, desmopressin is 
the only evidence‐based pharmaceutical therapy for nocturia.7 Despite this, the breadth of its 
use in clinical practice is limited.6, 8 Patients with nocturia have to face many hurdles before 
being diagnosed properly and treated with desmopressin, instead of OAB/BPO 
medication.6 Potential reasons for this, besides side effects, are the limited knowledge of 
clinicians regarding the drug and how to use it, and anxiety about safety, regardless of the 
evidence that with the available low‐dose formulations, hyponatremia is extremely rare, even 
in older patients.9, 10 There is a clear need for a summary of the available information and a 
simple algorithm on how desmopressin should be used in adults with nocturia. 
The aim of this paper, based on the International Continence Society’s (ICS) 2002 
document,1 is to: 
• 1) Summarize the nocturia patient pathway. 
• 2) Explore how nocturia is diagnosed and treated in the real world. 
• 3) Use the Delphi method to develop a practical algorithm based on the ICS’s 2002 
standardization of terminology in nocturia,1 with a focus on what steps need to be taken before 
prescribing desmopressin. 
2 METHODS 
An initial consultation between 12 urologists was held during the ICS 2017 meeting in 
Florence, with participants representing the ICS, ICI‐RS, European Association of Urology 
(EAU), and Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction 
(SUFU). Following the meeting, a nonsystematic keyword‐based literature search was 
performed using Google (search on “guidelines 2010‐2017” + symptom/sign/disease terms 
[edema, hypertension, heart failure, diet, menopause, male LUTS, OAB, prolapse, renal 
failure, diabetes insipidus, and diabetes mellitus]). All expert panel members were also 
invited to add any additional important guidelines from the different medical disciplines 
relevant to the diagnosis and treatment of nocturia and its underlying causes. Some of these 
guidelines specifically target nocturia, and others aspire to target the underlying cause. 
In areas where there was an absence of evidence and consistency between guidelines, the 
Delphi method was used to obtain an expert consensus—see Figure 1 for details. After the 
ICS 2017 meeting, a survey to gain views regarding the format, content, and additional panel 
members needed for the consensus report was distributed among nine of the urologists who 
agreed to participate as authors of the report, using the www.surveymonkey.complatform 
(round 1); 75% agreement was needed to reach a consensus. As part of this round, it was 
decided that a broader range of experts should be included in the panel for round 2 to provide 
a multidisciplinary perspective. The initial Delphi panel for round 2 comprised of 20 
clinicians, but 1 invitee did not respond to any of the rounds, and so the consensus was 
reached based on the views of the remaining 19 who participated. These 19 included 11 
urologists (9 from the original group), 1 gynecologist, 1 epidemiologist/physiotherapist, 1 
sleep specialist, 1 nephrologist, 1 geriatrician, 1 general practitioner, 1 neurologist, and 1 
pharmacist. The Delphi panel members were asked to indicate whether they agree or disagree 
with statements about the diagnosis and treatment of nocturia patients. Again, 75% of the 
panel had to agree to achieve a consensus. If there was a criticism of the statement/question, 
it was reformulated for an additional subround, of which there were 2 in round 2 (Figure 1). 
In round 3, a different set of statements were presented to the multidisciplinary Delphi panel, 
and the same level of agreement was needed (ie, ≥75%) for a consensus, but panel members 
were also asked to rate appropriateness of the statement on a scale of 1 to 9 (1‐3 
inappropriate; 4‐6 uncertain; 7‐9 appropriate). From the panel responses, a median 
appropriateness score was derived. As in round 2, if there was a criticism of the 
statement/question proposed, it was reformulated for an additional subround. 
 
Figure 1 
Open in figure viewerPowerPoint 
Summary of the Delphi process [Color figure can be viewed at wileyonlinelibrary.com] 
This consensus report on the diagnosis and treatment of nocturia is therefore based on real‐
life clinical practice, guideline/literature reviews, and where needed, an expert consensus 
obtained using the Delphi method. 
3 RESULTS 
The real‐life diagnostic and therapeutic pathways for nocturia patients, based on the 
underlying causes of nocturia,6 are summarized in Figure 2. There was a consensus that we 
should treat bothersome nocturia but there was no consensus on whether this should be 
confined to two or more voids per night, or include any level of nocturia. There was a 




Open in figure viewerPowerPoint 
Summary of the nocturia patient diagnosis and treatment pathways. Note that obesity can be 
indicative of excess caloric intake but is also associated with metabolic syndrome and is 
therefore also relevant to the cardiovascular pathway. Clinical specialities that deal with 
specific conditions may vary by country—for example, OSAS patients may be treated by a 
variety of specialists (including sleep, ear nose, and throat). BOO, bladder outlet obstruction; 
OAB, overactive bladder; OSAS, obstructive sleep apnea syndrome; RLS, restless legs 
syndrome [Color figure can be viewed at wileyonlinelibrary.com] 
3.1 Diagnostic packages 
The diagnostic packages in each subdiscipline dealing with nocturia patients are summarized 
below with reference to guidelines, prescribing information and the Delphi consensus—see 
Table 1 for an overview. History‐taking, physical examination, and clinical assessment 
including disease‐specific questionnaires (DSQ) are recommended diagnostic tools. The EAU 
2018 guidelines suggest the severity and bother of individual LUTS (nocturia) should be 
identified with a symptom score, supplemented by directed questioning if needed. Examples 
of nocturia‐specific questionnaires are the international consultation on incontinence 
questionnaire—nocturia; nocturia quality of life questionnaire, and the nocturia impact diary. 
In line with the diagnostic considerations from each of the relevant therapeutic areas, a 
questionnaire has recently been developed to help to unify approaches to nocturia 
diagnosis.11 The TANGO questionnaire is a short patient‐administered screening metric 
designed to help the clinician assess nocturia and diagnose these different contributory 
mechanisms. Although some further validation is needed, the tool is available for clinical use 
in English and Dutch, and validation in French and Spanish is ongoing. 















































































































































































Bladder diary + 3 d + 1. 
Consensus 
on the use 

























































































+ + • 1.Age 

















































































































































































































caution only in 
those with Class 
I mild 
congestive heart 






































































• Abbreviations: AVP, arginine vasopressin; BNP, brain natriuretic peptide; BOO, bladder outlet 
obstruction; CPAP, continuous positive airway pressure; dDAVP, desmopressin; DSQ, disease‐
specific questionnaire; FSH, follicle stimulating hormone; GFR, glomerular filtration rate; HRT, 
hormone replacement therapy; LH, luteinising hormone; LUTS, lower urinary tract symptoms; 
NP, nocturnal polyuria; NPI33, nocturnal polyuria index >33%; OAB, overactive bladder 
syndrome; OSAS, obstructive sleep apnea syndrome; PI, prescribing information; PSA, prostate‐
specific antigen; PVR, post‐void residual urine; RLS, restless legs syndrome. 
3.1.1 The lower urinary tract package 
History‐taking with or without the use of validated questionnaires is structured based on 
symptoms of the filling phase and the emptying phase of the bladder.12, 4 Physical 
examination focusses mainly on assessment of the prostate, vaginal examination for pelvic 
organ prolapse, and any urethral pathology, according to the relevant guidelines. 
The 2018 EAU male LUTS guidelines4 recommend to add urine analysis, serum prostate‐
specific antigen (PSA) test (if a diagnosis of prostate cancer will change the management), 
and to measure postvoid residual urine volumes. 
Three‐day bladder diaries, including sleep and wake up time, as well as the next morning’s 
first void, have been recommended as giving the optimal balance between compliance and 
reliability.13 The Delphi panel agreed (15/19) that it is necessary to demonstrate the presence 
of NP using a bladder diary before prescribing desmopressin. There was no consensus on the 
duration of bladder diary required, including on whether patients with cognitive impairment 
or impaired executive function warrant the use of a shorter duration of bladder diary. 
Approximately half of the panel (9/17) believe that all patients need to complete a 3‐day 
diary; while the remainder (8/17) believe that the diary period can be shortened if the patient 
had his/her symptoms during the observation day. In the latter case, it would be necessary to 
include a question in the bladder diary regarding whether this was a typical night for LUTS, 
or if it was better or worse than usual, for example, to give an indication of whether the case 
night was indicative of the patient’s condition. Even if there was an accurate questionnaire 
(>95% accuracy) that could predict NP, 13/18 (no consensus, 72%) would still ask patients to 
complete a bladder diary. This perseverance with the use of a bladder diary may reflect an 
underlying lack of conviction amongst the panel that such a questionnaire could feasibly be 
developed. 
The maximum voided volume, void frequency, and the ratio of nocturnal to 24‐hour urine 
production are the most used diary parameters to study and assess nocturia.14 A maximum 
voided volume of 350 mL is generally considered as reduced without real evidence to support 
this criterion. When the nocturnal urine production exceeds the maximum voided volume, 
then nocturia is predictable, with some safety margin (nocturia index of >1.3 is generally 
accepted as a reliable cut‐off).15 The frequent causes of reduced voided volumes include an 
OAB and residual urine (secondary to obstruction or detrusor underactivity). A residual urine 
measurement is, therefore, part of the initial assessment of nocturia.4 When reduced voided 
volumes are seen, imaging, urodynamics, and occasionally cystoscopy are performed, as 
appropriate. 
Excessive nocturnal or 24‐hour urine output is diagnosed using a bladder diary. According to 
the ICS definition, NP is diagnosed if more than one‐third (>33%) of the 24‐hour urine 
volume is produced during the night in patients over 65 years, and after excluding patients 
with 24‐hour polyuria (>40 mL/kg/d). In the United States, the FDA’s regulatory decision‐
making regarding desmopressin use has been based on these definitions. In younger people 
(21‐35 years) the cut‐off for NP is >20% of 24‐hour urine.1 No definition of NP between 
these age categories has been established. The “one‐third” definition in older people is the 
most widely used definition and has a high sensitivity but low specificity. Other definitions 
are available,16 but the most appropriate definition of NP is still the subject of much 
discussion.17, 18 However, the definition of NP is not the scope of this document. 
The Delphi panel considered that, in women, a pelvic examination is necessary before 
starting desmopressin either in all cases (7/19) or in those women with daytime symptoms 
(8/19)—an overall consensus of 15/19 in favor of pelvic examination. 
There was a consensus from the panel that a PSA check need not be standard in all older men 
before starting desmopressin (0/18); 7/18 answered that there is no need to check PSA and 
11/18 agreed that PSA measurement is only appropriate when considered necessary for other 
reasons. LUTS have no relation to PSA except in advanced prostate cancer (owing to the 
associated bladder outlet obstruction), and NP specifically is not associated with prostate 
cancer. 
There was a consensus that older men with nocturia should complete a DSQ (13/17, median 
7.4), post‐void residual (14/17, median 7.4), bladder diary is mandatory (14/17, median 8.7), 
and there was no consensus on the need for a digital rectal examination (10/17, median 7). 
3.1.2 Nephrological causes of nocturia and their diagnosis 
Renal causes of polyuria include renal diseases such as nephrogenic diabetes insipidus and 
loss of different circadian rhythms of the kidney, for example through aging of the 
kidney.19, 20 Nephrogenic diabetes insipidus can also be caused by some medications, 
including lithium. Renal failure can also lead to leg edema with NP as a consequence. 
When (nocturnal) polyuria is found, it is possible to diagnose the cause of the excess in urine 
output using renal function profiles.19 These renal function profiles help in distinguishing 
whether the excess in urine production is due to an increase in free water clearance 
(vasopressin‐related), osmotic diuresis (mainly salt, but can be urea [protein], glucose 
[diabetes], calcium [hypercalciuria], or lithium), or a combination. However, renal function 
profiles are only advised after the failure of desmopressin therapy, and for research purposes. 
In clinical practice, elevated free water clearance is the most frequent cause of NP throughout 
the lifespan and increases with age. The second most frequent etiology is an increased 
sodium clearance (eg, due to excess intake, leg edema, heart failure, hypertension, obstructive 
sleep apnea syndrome [OSAS], and medication), and this also increases with age. In 
summary, at first assessment, phenotyping (Figures 2 and 3) based on history taking, 
concomitant medication and a general physical examination help the clinician to implement 
lifestyle interventions and therapies such as desmopressin (assuming minimum glomerular 
filtration rate [GFR] of 50 mL/kg/min). 
 
Figure 3 
Open in figure viewerPowerPoint 
Phenotyping nocturia for uncontrolled causalities when prescribing desmopressin, based on 
guidelines, prescribing information or Delphi panel. *Based on evidence and guidelines to 
use CPAP for sleep apnea and the high levels of ANP and nocturnal salt loss. Conc, 
concentration; CV, cardiovascular; DI diabetes insipidus; DM, diabetes mellitus; Est, 
estrogen; E, efficacy; LUT, lower urinary tract; OSAS, obstructive sleep apnea syndrome; 
RLS, restless legs; S, safety; T, testosterone [Color figure can be viewed at 
wileyonlinelibrary.com] 
3.1.3 Hormones and nocturia 
Vasopressin is the main water‐regulating hormone in our body. Vasopressin deficiency and 
vasopressin resistance of nephrogenic (receptor) origin are the main mechanisms leading to a 
lack of antidiuretic response within the body. The result is 24‐hour polyuria and polydipsia, 
known as diabetes insipidus, which is a rare condition diagnosed via a bladder diary and a 
low morning (fasting) serum and urine osmolality. An abnormal circadian rhythm of 
vasopressin is the main mechanism for NP.21, 22 Asplund described a lack of circadian 
rhythm in patients with NP and nocturia in both men and women,23 but plasma levels in 
adults without nocturia peak at around 8 pg/mL in men and 4 pg/mL in women—both with a 
circadian rhythm.24 These levels fall and a gender difference becomes more obvious in 
adults, as described by Graugaard et al,24 and levels are even lower in the elderly, as 
described by Asplund. There is further evidence of an effect of the menstrual cycle in 
women,25 which may also increase female sensitivity to desmopressin. If doses are given in 
identical strengths in men and women (not measuring the dynamic endpoint of NP), we 
would expect more safety concerns in women, especially elderly women. Vasopressin itself is 
difficult to measure as a routine test; copeptin is a by‐product of vasopressin and is being 
explored as a biomarker of vasopressin levels. 
The sex hormones are also involved in regulation of diuresis.26 Deficiency in sex hormones 
(estrogen, testosterone) is diagnosed based on history taking and physical examination and 
can be confirmed with blood analysis. Some validated questionnaires are available for 
diagnosing menopause. Nocturia is not discussed in these guidelines.27 
3.1.4 Sleep and the central nervous system (CNS) as a cause of 
nocturia 
Sleep pathology, insomnia, and sleep disruption are well‐known causes of NP and 
nocturia,28, 29 and as such, they need to be diagnosed, especially as they are associated with 
morbidity and mortality.30-32 In epidemiological studies, nocturia is associated with restless 
legs syndrome.33 History taking and physical examination can be complemented with 
questionnaires including the Pittsburgh Sleep Quality Index,34 which screens for both 
nocturnal and diurnal symptoms related to sleep disorders. The Berlin questionnaire35 and 
the STOP questionnaire36 are screening tools for OSAS. Polysomnography is performed 
when a diagnosis of sleep disorders is suspected. 
Parkinson’s disease and restless legs syndrome are conditions characterized by a dopamine 
deficiency.37, 38 Sleep disruption and deprivation are associated with low dopamine levels in 
the central nervous system.39 Both Parkinson’s disease and restless legs syndrome are 
associated with NP and a reduced bladder capacity due to OAB and sphincter dysfunction.40-
42 However, a recent study suggested that the prevalence of NP in Parkinson’s disease is no 
higher when compared with a control population, indicating some uncertainty in this 
regard.43 The diagnosis of a brain‐ or sleep‐related cause of nocturia is made clinically, and 
when suspected, patients need to be referred to neurologists or sleep specialists. 
Evidence‐based medicine6 supports the need to refer and diagnose nocturia patients with 
suspected obstructive sleep apnea. Among the Delphi panel, there was no consensus whether 
suspected restless legs syndrome required a referral (9/17 [6 would treat NP simultaneously 
with referral]) or simply initiation of treatment for NP (8/17). 
3.1.5 Cardiovascular causes of nocturia 
Hypertension is associated with nocturia and NP.22 Nondipping hypertensive patients are a 
subgroup who do not exhibit a nocturnal reduction in blood pressure. There is an association 
between nondipping hypertension and nocturia,44 and a specific association has been 
reported between NP and nondipping hypertension.45 Children with enuresis have also been 
found to have higher nocturnal blood pressure than controls.46 Nondipping hypertension is 
associated with increased morbidity.47 In addition, postural hypotension with low blood 
pressures when standing results in higher blood pressures when supine. Diagnosis is simply 
made by measuring the blood pressure as part of the general clinical examination. Available 
guidelines in this area do not discuss nocturia.48-53 
The metabolic syndrome is strongly associated with nocturia and many conditions 
predisposing to NP,54, 55 and it is an important burden for healthcare systems worldwide. 
The condition needs to be diagnosed when clinically suspected in patients with nocturia. 
Again, available guidelines in this area do not mention nocturia.57, 56 
Heart failure often coincides with renal failure (30%‐40%) and correlates with increased 
mortality. This cardio‐renal syndrome presents as elevated brain natriuretic peptide (BNP) 
with hypovolemia (normal serum sodium) or as overfilling (hyponatremia). Both conditions 
coincide with an elevated creatinine, a bad estimator of GFR in these patients, and demand 
referral before initiation of desmopressin or timed diuretic therapy.58 
Right‐sided heart failure, in particular, is characterized by fluid retention and swelling of the 
abdomen, legs, and feet (https://www.mayoclinic.org/diseases‐conditions/heart‐
failure/symptoms‐causes/syc‐20373142). Edema, and especially leg edema, causes NP and 
nocturia through resorption of fluid when supine,59, 60 resulting in an immediate excess in 
urine output and a delayed increase in ANP‐related salt diuresis. Leg edema is seen with 
liver, heart or kidney disease or following varices of the legs, lack of physical activity or 
muscle paralysis. Concomitant medications that can cause edema are listed in the section 
below on concomitant medication. Diagnosis of edema is based on expert opinion rather than 
empirical evidence, and the available guideline documents for edema do not mention 
nocturia.48, 49 
As mentioned above, there was a consensus that older men with edema and nocturia should 
complete a DSQ (13/17), have a postvoid residual measurement (14/17), and a clinical 
evaluation of cardiovascular and leg edema (13/17); a bladder diary is mandatory (17/17). 
There was no consensus on a digital rectal examination (10/17). There was a consensus that 
older people with nocturia should have their blood pressure measured (13/17, median 
appropriateness 8). Older people with leg edema and nocturia were considered likely 
candidates for cardiovascular aetiological factors (13/17, median appropriateness 7), and it 
was agreed that clinical examination should focus on this pathophysiology (13/17, median 7). 
3.1.6 Fluid and food intake as a cause of nocturia 
High intake of water, salt, or protein results in an increased excretion by the kidney and can 
result in NP and nocturia. An excess intake of osmoles leads to thirst, and increased fluid 
intake—a second reason for NP. An excess intake of calories results in obesity which may, 
even without the presence of the metabolic syndrome, result in NP due to the higher intra‐
abdominal pressure, mainly when supine, as a result of obstruction of the respiratory 
tract.61 History taking, physical examination, recording of fluid and food intake on a bladder 
diary, and hypothetically renal function profiles can diagnose the excess of intake of sodium 
(salt) and ureum (protein).62, 63 
Dietary guidelines discuss the treatment of obesity56, 64 but nocturia‐related 
recommendations are not available. The consensus panel agreed that it is appropriate (13/17, 
median appropriateness 7) to investigate caloric intake and physical activity through history 
taking and/or diaries. 
3.1.7 Concomitant medication leading to nocturia 
Concomitant medication is often difficult to interrupt or change but might have an important 
impact on nocturia through increasing or decreasing diuresis, changing bladder function, or 
through interfering with sleep. Other factors that will influence the impact of concomitant 
medication are the timing of administration, mode of administration, formulation (long‐ vs 
short‐acting), and so on. Most of these factors have not been well studied.3, 14 
For many medications, the net result on diuresis (water and osmotic diuresis) is unknown and 
insufficiently studied, and many medications have contradictory effects on water and osmotic 
diuresis. Even desmopressin, known to solely impact on free water excretion, can cause water 
retention resulting in renin‐angiotensin‐aldosterone system suppression, ANP, release and 
osmotic diuresis. 
Another example of the contradictory effects of concomitant medication is calcium channel 
blockers—these increase salt excretion65 to lower blood pressure, but side effects include leg 
edema, which can potentially worsen nocturia when the edema fluid is resorbed during the 
night. 
Medications that typically increase diuresis are diuretics, all antihypertensive medication, 
progesterone, melatonin, lithium, and SECT‐2‐inhibitors (antidiabetic patients).6 Other 
medications decrease diuresis, such as the older antidiabetic patients, antidepressants, 
antiepileptics, estrogens, testosterone, corticoids, and nonsteroidal anti‐inflammatory drugs 
(NSAIDs). 
Medications that typically cause leg edema are antidepressants (monoamine oxidase 
inhibitors, trazodone), antihypertensives (beta‐blockers, clonidine, hydralazine, methyldopa, 
minoxidil and so on), antivirals (acyclovir), hormones (sex hormones), NSAIDs (celecoxib, 
ibuprofen), and some chemotherapeutics and cytokines.6 
There is a consensus that the following conditions are a contraindication for desmopressin: 
congestive heart failure (16/19), polydipsia (15/19), and concomitant medication with a high 
risk of hyponatremia (16/19).66 There was no consensus for peripheral edema (12/19), 
uncontrolled hypertension (13/19), uncontrolled diabetes (11/19), and oral steroids (6/19). 
For nasal/inhalation steroids there was a reversed consensus (0/19). 
Diagnostic packages: 
• Consensus on history taking or questionnaires for all causalities. 
• Pelvic (women) or rectal (men) examination when judged necessary. 
• Blood pressure and edema check is necessary. 
• Consensus for bladder diary, but not for its duration (3 days suggested). 
• Consensus for diaries on sleep, intake (fluid and food), and physical activity. 
• Consensus for postvoid residual measurements. 
• PSA, serum sodium check (SSC), renal/heart function, and endocrine screening when judged 
necessary. 
• Timing or empty stomach when SSC performed is not important. 
3.2 Therapeutic packages 
Lifestyle interventions targeted towards the aetiology of nocturia may be useful in some 
patients (Figure 4). 
 
Figure 4 
Open in figure viewerPowerPoint 
Lifestyle interventions in nocturia according to pathophysiology. DM, diabetes mellitus 
[Color figure can be viewed at wileyonlinelibrary.com] 
3.2.1 Lower urinary tract therapy 
There is level two evidence that treating dysfunctions of the bladder and the prostate (eg, 
OAB and BPO) with lifestyle interventions such as bladder training and pelvic floor training, 
or evening exercise (eg, walking the dog), as well as medication or surgery, improve 
nocturia.6 
There was a consensus from the panel that combination therapy should be considered for 
nocturia that is refractory to initial treatment (18/19). 
3.2.2 Nephrological causes of nocturia and their therapy 
Lifestyle interventions aim to prevent rather than treat renal disorders, for example by 
avoiding obesity, hypertension, and diabetes. Salt, protein, and caloric restriction are advised 
in patients with renal failure but there is no evidence of its effect on nocturia. Desmopressin 
can have some effect in partial nephrogenic diabetes insipidus but is not the primary choice in 
patients with severe renal failure as the risk of hyponatremia is much higher (Table 3). For 
those undergoing an investigation of renal function, there was a consensus that desmopressin 
should not be prescribed if eGFR is <50, and that higher limits are dependent on local 
prescribing information. In patients with low to moderate renal failure, as is seen in most of 
the older population, a loss of circadian rhythms in diuresis is found and these patients are 
potentially good candidates for desmopressin therapy. 
3.2.3 Hormones and nocturia therapy 
In the 2002 standardization document,1 low estrogen and menopause are recognized as a 
cause of nocturia, and androgen deprivation is also associated with LUTS and nocturia. There 
is no evidence‐based medicine to demonstrate that hormonal substitution in postmenopausal 
women is an effective treatment of nocturia (ICI‐RS 2017).26 The 2015 NICE guidelines 
(https://www.nice.org.uk/guidance/ng23) state that there is a good evidence that hormonal 
substitution is helpful for vasomotor symptoms (hot flushes) and for vaginal atrophy and its 
consequences, but do not mention nocturia. 
There was a consensus that menopause‐related nocturia and hot flushes should be treated 
with lifestyle interventions and hormone replacement therapy (17/18). These approaches 
were not considered useful when menopause is asymptomatic, except for nocturia (5/18). 
Desmopressin should not be given during the first treatment consultation in the presence of 
menopausal symptoms (1/18 if menopausal symptoms), but when there is nocturia without 
menopausal symptoms, there was nearly a consensus that desmopressin can be given (13/18 
[74%]). 
Patients with NP due to a blunted increase in AVP secretion at night, leading to an increase in 
free water clearance, are good candidates for desmopressin therapy.67 Patients with 24‐hour 
polyuria due to central diabetes insipidus (in which production of AVP is compromised) are 
also effectively treated with desmopressin,68 which is in these cases a type of hormone 
replacement therapy. 
3.2.4 Sleep and the CNS in nocturia therapy 
There is level 1a evidence for the use of CPAP in patients with OSAS. There is only low 
level 2 or lower level evidence that sleep aids, treatment of low dopamine and treatment of 
restless legs syndrome have an impact on nocturia (ICI‐RS 2015).42 
There was a lack of consensus from the panel regarding the treatment of patients with 
insomnia, nocturia, NP, and a diagnosis of RLS. There was no consensus (10/17) whether 
patients with insomnia and NP should be treated for insomnia and with desmopressin at the 
same time (median appropriateness was 7). There was no consensus on treating RLS, 
insomnia, insomnia with RLS, or NP with RLS and insomnia in any combination. 
In patients with insomnia, nocturia, and NP without a diagnosis of RLS, there was a 
consensus to treat NP (14/17) but this was split across treatment of NP per se (8/17), referral 
to a sleep clinic (3/17), or both (6/17). Reasons for this lack of agreement across the panel on 
the appropriate steps may relate to a lack of evidence on which to base treatment of insomnia 
with nocturia/NP, or perhaps to the range of specialisms in the group with inconsistent views 
on the role of other disciplines, e.g., for example, sleep medicine. 
3.2.5 Cardiovascular causes of nocturia and their therapy 
There is ample evidence that treating heart conditions, increasing physical activity, salt 
restriction, losing weight, and preventing edema treats nocturia.6 
Desmopressin for nocturia is contraindicated in patients with mild (class II) to severe (class 
IV) congestive heart failure (New York Heart Association Class II to IV) or uncontrolled 
hypertension, and should be used with caution (eg, monitoring of volume status) in patients 
with New York Heart Association Class I mild congestive heart failure because of the risk of 
fluid overload and electrolyte abnormalities. Patients with heart failure may also be at 
increased risk for low sodium concentrations.69 
In people with moderate cardiac failure, there was a consensus that this condition should be 
treated before any attempt to address nocturia specifically (16/17, median 9). Use of 
desmopressin in such cases is completely inappropriate (16/17, median 2). There was no 
consensus concerning the use of daytime furosemide (4/17, median appropriateness 5). 
In older people with NP, nocturia, and hypertension, there was no consensus as to whether 
hypertension should be treated first (11/18, median appropriateness 7). Treatment of NP first 
was considered inappropriate by 8/17 (median 4). The treatment of hypertension and NP 
simultaneously also had no consensus (5/17 inappropriate, 6/17 uncertain, and 6/17 
appropriate; median appropriateness 5). The Delphi panel did not consider it useful to change 
antihypertensive drugs or their timing (other than diuretics) (8/17, median 6) to address 
nocturia. 
In patients with varicose veins but no cardiac failure, there was no consensus on treating 
veins first (9/18, median 6) nor on using desmopressin first (10/17 inappropriate, 3/17 
uncertain, and 4/17 appropriate; median 4). 
3.2.6 Intake as a target of nocturia therapy 
Limiting excess fluid intake and changing the type of fluid is advised in most LUTS 
guidelines.70 Less is known about the effect of diet and weight loss.6 Weight loss will 
decrease hyperfiltration and diuresis. Low protein intake will decrease salt and ureum output 
and osmotic diuresis. Salt restriction might decrease osmotic diuresis. Low carbohydrate 
intake will not change diuresis directly. Low fat intake will not directly affect diuresis. 
During most diets, an increase in water intake is advised, increasing water diuresis. In 
conclusion, from a theoretical, nonevidence‐based viewpoint, a protein‐rich and 
fat/carbohydrate‐restricted diet might increase urine output as well as reduce it in the longer‐
term via weight loss. A well‐balanced calorie‐restricted diet seems the most logical approach 
to avoid high excretion of ureum and salt in patients with nocturia. In general, guidelines 
suggest caloric restriction and summarize that a high protein intake results in more efficient 
weight loss.57, 56 
There was no consensus from the Delphi panel on appropriate therapeutic options for patients 
with high BMI and nocturia (including losing weight [no consensus 9/18, median 
appropriateness 6]; weight loss with desmopressin [5/18, median 5]; desmopressin alone 
[6/18, median 5]; and adapting diet when there is a high osmotic load [6/18, median 5]). 
Therapeutic packages: 
• There is only good evidence for desmopressin and for CPAP. 
• For all other therapies, the evidence is moderate (furosemide, OAB‐BPH medication) or weak for 
most causalities. 
• The safe candidates for desmopressin can be phenotyped as no polydipsia, heart/kidney failure, 
severe leg edema, or OSAS. 
3.3 Initiating desmopressin treatment 
NP due to reduced nocturnal vasopressin is the primary target for desmopressin. Salt‐related 
NP is associated with other causes such as sleep apnea (the primary target for CPAP), edema, 
obesity, hypertension, heart failure, and high salt intake. There is level 1a evidence that 
desmopressin and CPAP treat nocturia.7, 4 A summary of the prescribing information for 
available desmopressin formulations for nocturia from the United States, Australia, and 
Europe is given in Table 2. 
Table 2. Prescribing information for different desmopressin formulations indicated for 









Age for baseline 
sodium checks and 
follow up 
65 65 65 
Fluid restriction Restrict Moderation advised (do not 
drink large amounts close to 
bedtime) 
Restrict 1 h before to 8 h 
after administration 
GFR (lower limit for 
prescribing) 
50 or 60a 50 50‐60a 
Sodium checks after 
baseline (≥65 y) 
3 d + after uptitration Within 7 d + after uptitration 4‐8 d + 1 mo or 4‐8 d, 1 mo, 
every 3 to 6 months, 
depending on clinical need 
Cardiovascular 
contraindication 
Cardiac insufficiency or 
conditions requiring 
diuretics 
NYHA class II or higher 
CHF 
Heart failure, edema 
Diuretic use 
Frail elderly Not mentioned Not mentioned Contraindicated 
• CHF, congestive heart failure; GFR, glomerular filtration rate; NYHA, New York Heart 
Association 
• a Moderate to severe renal failure or <50‐60 mL/min depending on the formula used and cut‐off 
used. 
The panel agreed that bothersome nocturia should be treated (17/19); however, there was no 
consensus regarding what level of severity warrants treatment (≥2 voids/night [5/19], or any 
nocturia [12/19]). It was agreed that nonbothersome nocturia or convenience voids (ie, 
secondary to waking for a different reason) should not be treated with desmopressin (1 and 
0/19). 
There was no consensus among the Delphi panel as to an appropriate age limit above which 
serum sodium should be checked before desmopressin treatment. This was also true for renal 
function (eGFR). This lack of consensus is likely affected by differences in prescribing 
information and recommendations between countries. However, there was a consensus that 
any age limit should not be treated too stringently, and patients who are near the limit may 
also be checked before treatment (17/19). 
The Delphi consensus was that patients with a baseline serum sodium of ≤130 mmol/L should 
not be prescribed desmopressin (18/19), with the panel split between a cut‐off of 
>130 mmol/L (6/19) and >135 mmol/L (12/19) for treatment. Again, the panel’s views on this 
issue might be influenced by regional regulatory rules and prescribing information. 
Dilutional hyponatremia takes several days of positive water balance to build up. To decrease 
by 5 mmol/L a positive water balance of 2 L is needed. There was a consensus (15/17) that 
SSCs can be performed at any time of day and are not affected by whether or not the stomach 
is empty (although note that polydipsia is a contraindication of the drug). There is sufficient 
literature to support that a sodium check can be done at any time of the day.71 
The following conditions are agreed to be contraindications for desmopressin use: congestive 
heart failure (16/19), polydipsia (15/19), and concomitant medication with a high risk of 
hyponatremia (16/19). Concomitant medication with low risk for hyponatremia (5/19), 
peripheral edema (12/19), uncontrolled hypertension (13/19) or diabetes (11/19), oral steroids 
(6/19), and nasal steroids (0/16) did not reach consensus. 
The panel agreed that women are more prone to hyponatremia and that this should have 
implications for desmopressin therapy and its follow‐up (16/19). There is a consensus that 
some form of fluid restriction is needed by patients prescribed desmopressin (18/19)—either 
following thirst (14/19) or strict fluid restriction (4/19). 
With earlier formulations of desmopressin (0.2 mg tablets), hyponatremia was seen mainly in 
older populations, leading to a restriction in use to those below 65 years of age. Lowering the 
dose to provide an antidiuretic effect of 6 to 8 hours was the logical way to treat the older 
(especially female) population. Low dose therapy is not a well‐defined term but is today the 
best way to describe the newer formulations in the market, which have both been tested in an 
older population. Low dose therapy is advisable in older (but not frail) patients and serum 
sodium monitoring is needed; such monitoring can be individualized depending on patient‐
specific factors (eg, age, concomitant medication) and comorbidities (16/19). Frail older 
patients with bothersome nocturia and comorbidities or other risk factors should first be 
treated for other issues and comorbidities and then, if still required, desmopressin should be 
initiated with careful monitoring (15/18). 
Young healthy patients can be treated with any licensed desmopressin formulation (15/18). 
Initiating desmopressin: 
• Risk management consensus on classification into three clinical pictures: (1) standard vigilance to 
symptoms of hyponatremia, (2) SSC, and (3) contraindications. 
• Decision‐based on age, renal function, heart failure, frailness, edema, baseline serum sodium, 
drinking habits, and medication. 
• Low‐dose formulations preferred in patients needing SSC. 
3.4 Follow‐up of desmopressin therapy 
Critical to the appropriate use of desmopressin and its analogs is an established schema for 
monitoring of sodium homeostasis in the acute and chronic phase of therapy. Contingent on 
stable dosing and otherwise unchanging comorbidities is the realization that shifts in fluid 
ingestion may potentiate the risk of hyponatremia in an otherwise stable patient. Therefore, 
an informed and the engaged patient is critical to desmopressin safety. In addition, acute 
alterations in concomitant comorbidities should be assessed for their potential to impact 
sodium levels. 
There are various approaches to sodium monitoring in the literature. Before starting therapy, 
baseline sodium levels must be obtained in patients at risk for hyponatremia. Bioavailability 
and formulation delivery appear to have an impact on desmopressin half‐life and the area 
under the curve (indicative of drug exposure), both of which impact the risk of 
hyponatremia.17 There is some evidence from analysis of a merged database17 that a sodium 
monitoring plan should begin with a baseline sodium ≥135 mmol/L with additional SSC at 
week 1 and month 1 after initiation of desmopressin in patients who are at increased risk (eg, 
due to older age, or concomitant medications). This conclusion is based on the fact that most 
clinically significant cases of hyponatremia were seen within 2 to 3 weeks of treatment 
initiation. A noteworthy observation is that time to return to normal after cessation of 
treatment was a median of 17 days (range 8‐28). 
As the optimal monitoring schedule is often debated, the Delphi panel was consulted. When 
baseline serum sodium levels were judged necessary, there was a consensus that serum 
sodium should be checked on a fixed schedule, beginning within 7 days of desmopressin 
initiation, but with no consensus regarding exactly when in the first week this should occur 
(Day 3 [7/19] or Day 5‐7 [9/19]). Weekly blood samples were not deemed necessary (1/18); 
4/18 preferred 2‐weekly and 13/18 (or 72%; no consensus) agreed that samples should be 
taken at the discretion of the physician. There was a consensus to perform an SSC as judged 
by the clinician at 1 month (17/18). Beyond 1 year, there is no consensus on follow up 
required—10/18 agree that monitoring should be performed when the patient’s medical 
condition (eg, hospitalization, fever) or concomitant medication changes; 8/18 agreed with 
annual checks. 
In young healthy patients, there was no consensus on SSC needed—the majority believed no 
checks were necessary (11/18), assuming no underlying medical conditions. 
There was a consensus that some form of fluid restriction should be advised for all patients 
(only 1/18 found it unnecessary)—the consensus was split between advising patients to 
follow their own thirst (14/18) and strict fluid restriction (4/18). 
If the response to desmopressin is insufficient at a low dose, there was a consensus that dose 
should be up‐titrated (18/19), depending upon the frailty of the patient (11/19). An SSC 
should be carried out before up‐titration, depending on the patient (17/19). If the dose is up‐
titrated and further sodium checks are appropriate (15/19), these should be carried out within 
7 days. 
If hyponatremia is found after initiating desmopressin therapy, there is a consensus (15/19) 
that treatment should be discontinued when an SSC is below 130 regardless of the presence 
of symptoms. If sodium check is between 130 and 135 and the patient is asymptomatic, 
treatment need not be discontinued (only 1/19 would stop the therapy), but further checks 
(8/19) or drug‐free intervals (3/19) or lowering the dose (7/19) should be performed. See 
Figure 5 for a summary. 
 
Figure 5 
Open in figure viewerPowerPoint 
Follow‐up after desmopressin prescription when serum sodium checks wanted or needed. 
Symptoms of hyponatremia include: nausea and vomiting, headache, confusion, loss of 
energy, drowsiness, and fatigue, restlessness and irritability, muscle weakness, spasms or 
cramps, seizures, and coma. FU, follow up; SSC, serum sodium check [Color figure can be 
viewed at wileyonlinelibrary.com] 
Follow‐up of desmopressin therapy: 
• If SSCs are necessary, follow‐up on day 3 to 7 and 1 month. 
• Further checks at clinician discretion. 
• Stop therapy if serum sodium is <130 mmol/L regardless of hyponatremia symptoms, and if serum 
sodium is 130 to 135 mmol/L with symptoms. 
3.5 Patient‐oriented nocturia care path 
Based on existing guidelines, evidenced‐based medicine, and the Delphi panel, we developed 
a patient‐oriented multidisciplinary diagnostic and therapeutic algorithm for bothersome 
nocturia, aiming for a more holistic approach to nocturia from a multidisciplinary angle 




Open in figure viewerPowerPoint 
A patient‐oriented multidisciplinary diagnostic and therapeutic algorithm for nocturia. *If 
desmopressin, consider Figure 3 and Table 3 before initiating, and consider Figure 5 for 
follow‐up. BD, bladder diary; BNP, brain‐derived natriuretic peptide; BOO, bladder outlet 
obstruction; BPS, bladder pain syndrome; Con Med, concomitant medication; CPAP, 
continuous positive airway pressure; CV, cardiovascular; DI, diabetes insipidus; DM, 
diabetes mellitus; DSQ, disease‐specific questionnaires; DVT, deep venous thrombosis; 
ECG, electrocardiogram; GFR, glomerular filtration rate; HRT, hormone replacement 
therapy; LUT(S), lower urinary tract (symptoms); MS, multiple sclerosis; OAB, overactive 
bladder; OSAS, obstructive sleep apnoea syndrome; PSA, prostate‐specific antigen; PSG, 
polysomnography; PVR, post void residual; RLS, restless legs syndrome. 
consensus,  consensus “when judged necessary by the clinician,” “combinations possible” 
[Color figure can be viewed at wileyonlinelibrary.com] 
4 DISCUSSION 
Diagnostic and treatment packages (Figure 2) are helpful in the visualization of the pathway 
of nocturia patients. We believe they could be a useful educational tool for training of 
healthcare professionals to improve patient care for nocturia, to limit the hurdles a patient has 
to get over to receive appropriate care and decrease the time to treatment. 
The lifestyle interventions that are recommended in all LUTS guidelines are a good case in 
point. There is a growing interest globally in lifestyle interventions as a possible treatment for 
LUTS and, therefore, also for nocturia. The International Consultation on Incontinence 
summarized the need for research on conservative management of incontinence,72 and the 
possible lifestyle interventions that can be relevant in nocturia are weight loss, diet change, 
fluid intake modification, and exercise. Of these, weight loss and fluid management have a 
fair amount of scientific data to support their impact. Weight loss (Level 1 evidence) is 
mentioned as a first‐line treatment to reduce the prevalence of urinary incontinence with a 
Grade A recommendation. Restricted fluid intake, which could decrease the voiding 
frequency, urgency, and volume is mentioned with a Grade B recommendation. For nocturia 
specifically, no such high levels of evidence exist, with the exception of fluid restriction 
(Level 1b). In contrast, expert opinion supports weight loss, diet, foods, salt restriction, and 
protein restriction in the therapy of nocturia.6 This shows an important scientific knowledge 
gap in our understanding of approaches to the reduction of LUTS and nocturia. 
There are a number of strategies to manage the risk associated with desmopressin therapy 
(namely hyponatremia risk). In young healthy people with nocturia, it is advised that any 
desmopressin formulation can be used, and dose can be up‐ or down‐titrated when needed. In 
older people, the factors summarized in Table 3 should be checked, and a low dose 
formulation should be used or the patient should be excluded from desmopressin therapy. It is 
safer to start with a lower dose and to lower the threshold to perform SSC in women 
compared with men as women have a higher sensitivity to desmopressin and are more prone 
to hyponatremia. This gender difference in antidiuretic response has been found in animal 
studies73 and in clinical studies.74, 75 In female rats, it was shown that this gender 
difference is explained by a significantly higher expression of the V2 receptor in 
females.73 It was suggested that this was caused by escape from X‐chromosome inactivation 
by the X‐linked V2R gene, causing increased V2R dosage in females.76 







Standard vigilance to 
hyponatremia 
symptoms +  serum 
sodium check (SSC) 
Contraindication 
 
< 65 y 65 y or older Frail older people 
 
Baseline sodium > 135 Baseline sodium 130‐135 Baseline sodium below 130 
 
eGFR > 50‐60 eGFR 50‐60 eGFR <50 
 
No concomitant 
medication that can cause 
hyponatremia 
Concomitant medication weakly 
or moderately related to 
hyponatremia 
Concomitant medication 
strongly related to 
hyponatremia 
 
No leg edema Low to moderate leg edema Important leg oedema 
 
No heart failure Heart failure (NYHA class I) Heart failure (NYHA class 
II or higher) 
 
No diabetes mellitus or 
hypertension 
Controlled diabetes mellitus or 
hypertension 
Uncontrolled diabetes 
mellitus or hypertension 
  











Standard vigilance to 
hyponatremia 
symptoms +  serum 
sodium check (SSC) 
Contraindication 
Formulation Any desmopressin 
formulation 
Low dose desmopressin Treat condition if possible 
and wait with desmopressin 
SSC No consensus on SSC Consensus on SSC – 
High‐risk medications for hyponatremia are thiazide diuretics, lithium, valproate, and 
carbamazepine66 and use of these should be considered as a contraindication for 
desmopressin therapy. Low‐to‐moderate risk medications for hyponatremia are loop 
diuretics, antidepressants, ACE‐inhibitors, and angiotensin‐II‐receptor blockers. These can be 
used concomitantly with desmopressin after consideration of the other factors from Table 3; 
concomitant use necessitates follow‐up and sodium monitoring. Based on studies with loop 
diuretics,6 it is wise not to start both medications at the same time, but to allow an interval of 
2 to 3 weeks between their initiation to help the kidney in resetting its salt gradient before 
administering the second drug. 
Since it is important to consider the frail elderly as distinct from other older persons for the 
purpose of desmopressin therapy, a definition of what is meant by frailty would be helpful. 
Perhaps the combination of a clinical frailty scale and a Timed Up and Go test (to assess a 
person’s mobility using static and dynamic balance) would capture enough about frailty for 
most clinicians. The modified frailty index is an 11 item frailty index described for noncancer 
gynecological patients which captures enough information to detect adverse outcomes and 
this might be useful.77 There is also the G8 survey, which captures “frailty.”78 Regarding 
comorbid conditions, a Charleston comorbidity index would be of use, although it is 
somewhat limited in older people by a lack of variability. 
In the consideration of heart failure and its diagnosis in nocturia patients, heart failure should 
be suspected when there is a history of heart disease, when edema and/or weight gain with 
rapid onset is found and/or a patient complains of exertional dyspnea or orthopnea. A normal 
serum BNP concentration rules out uncontrolled heart failure. It is clear that when this 
condition is suspected, even in mild form, clinicians should be careful with prescribing 
desmopressin and it is better to refer the patient to a cardiologist and await instructions. 
The monitoring of serum sodium in nocturia patients treated with desmopressin lacks 
sufficient evidence to produce good guidelines. As hyponatremia is rare in well‐selected 
patients with the currently available low‐dose formulations, producing strong evidence for a 
safety protocol will be difficult. It is likely that complex statistical studies on merged 
databases may be a promising strategy for the future and could help to produce a personalized 
medicine algorithm for serum sodium monitoring after desmopressin initiation. In the 
meantime, clinicians should err on the side of caution, even if it means more SSC. 
From a clinical scientific perspective, when looking at Table 2, it would be interesting to 
demonstrate the actual plasma levels of desmopressin following the use of the three different 
formulations, as this explains better the rationale for the dose differentiation. We would 
suggest focussing on pharmacodynamic studies combined with pharmacokinetic studies to 
evaluate the strength and duration of the antidiuretic effect, and the effect on serum sodium 
levels. These studies would ideally be performed in nocturia patients during an overnight 
evaluation, as performed by Goessaert et al.79 
It is clear from this Delphi panel experience that items which suffer from a lack of evidence 
in the literature are difficult to form a consensus on with a multidisciplinary panel. This 
demonstrates the need for more studies on some of the smallest steps in the care path of 
nocturia patients. However, the performance of studies that are crucial to our understanding, 
but do not attract funding from the pharmaceutical industry (eg, effects of lifestyle 
interventions), will be challenging, as will be the study of low‐frequency events and patient 
risk factors. There is also a difficulty in reaching consensus in relation to diagnostic tests such 
as serum PSA or clinical prolapse evaluation as the guidelines in these areas originated from 
urological or gynecological organizations (and indirectly from studies on urological and 
gynecological patients), whereas the Delphi panel is multidisciplinary and clearly votes from 
this broader perspective. Our algorithm needs more research mainly in relation to the 
causalities of the cardiovascular system and intake‐related aetiologies. Even in 
urogynecology, many questions remain unanswered such as the efficacy of medication in 
nocturia patients with a reduced bladder capacity. For sleep disorders, little research has been 
done on restless legs syndrome and insomnia as a cause of nocturia. Finally, there is a need to 
study nocturia based on this multicausal origin, as well as from a diagnostic and a therapeutic 
angle. Development of a standalone evidence‐based nocturia guideline will probably 
originate from a multidisciplinary organization, and in the future, we envisage that the 
nocturia care path will move away from the disciplines of urology and gynecology towards 
less narrowly focused specialisms such as internal medicine, geriatrics, and general practice. 
5 CONCLUSION 
A summary of the nocturia patient pathway across different medical specialisms is useful in 
the visualization and phenotyping of patients for diagnosis and therapy. It also highlights that 
nocturia is in general not a urological symptom, but predominantly a symptom of a wide 
variety of causalities, many of which are easy to screen for with history taking, 
questionnaires, and physical examination. By providing some basic knowledge of 
desmopressin, its contraindications, safety concerns and follow‐up here, we aim to ease its 
initiation for clinicians and to shorten the patient journey for nocturia. 
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• 1The nocturia definition was recently updated by the International Continence Society (see 
the article by Hashim et al4) as: The number of times urine is passed during the main sleep 
period. Having woken to pass urine for the first time, each urination must be followed by 
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